Chlorpromazine versus piperacetazine for schizophrenia
Cochrane Database of Systematic Reviews, 2018•cochranelibrary.com
Background Schizophrenia is a severe mental disorder with a prevalence of about 1%
among the general population. It is listed among the top 10 causes of disability‐adjusted life
years (DALYs) worldwide. Antipsychotics are the mainstay treatment. Piperacetazine has
been reported to be as clinically effective as chlorpromazine, a well established'benchmark'
antipsychotic, for people with schizophrenia. However, the side effect profiles of these
antipsychotics differ and it is important that an evidence base is available comparing the …
among the general population. It is listed among the top 10 causes of disability‐adjusted life
years (DALYs) worldwide. Antipsychotics are the mainstay treatment. Piperacetazine has
been reported to be as clinically effective as chlorpromazine, a well established'benchmark'
antipsychotic, for people with schizophrenia. However, the side effect profiles of these
antipsychotics differ and it is important that an evidence base is available comparing the …
Background
Schizophrenia is a severe mental disorder with a prevalence of about 1% among the general population. It is listed among the top 10 causes of disability‐adjusted life years (DALYs) worldwide. Antipsychotics are the mainstay treatment. Piperacetazine has been reported to be as clinically effective as chlorpromazine, a well established'benchmark'antipsychotic, for people with schizophrenia. However, the side effect profiles of these antipsychotics differ and it is important that an evidence base is available comparing the benefits, and potential harms of these two antipsychotics.
Objectives
To assess the clinical and side effects of chlorpromazine for people with schizophrenia and schizophrenia‐like psychoses in comparison with piperacetazine.
cochranelibrary.com